Iofina Share Price. IOF - Stock Quote, Charts, Trade History, Share Chat, Financials. Iofina Plc

Gold vs US Dollar

LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

Home
Investing
Stocks
UK
LSE
Iofina Plc (IOF)
Iofina Plc (IOF) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Iofina Plc	LSE:IOF	London	Ordinary Share	GB00B2QL5C79	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.50	-1.44%	34.25	94,115	13:43:50

Bid Price		Offer Price	High Price	Low Price	Open Price
34.00		34.50	34.75	34.25	34.75

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Offices-holdng Companies,nec	42.20	7.87	-	8.69	65.71

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
16:00:22	O	5,853	34.17	GBX

Related Shares
Croda (CRDA), Johnson Matthey (JMAT), Byotrol (BYOT), Hardide (HDD)

Iofina (IOF) Latest News

Iofina News

Date	Time	Source	Headline
09/5/2023	07:00	UKREG	Iofina PLC Notice of AGM
04/5/2023	07:00	RNSNON	Iofina PLC Investor Presentation
28/4/2023	16:45	UKREG	Iofina PLC Holding(s) in Company
28/4/2023	07:00	UKREG	Iofina PLC Grant of Share Options
25/4/2023	14:54	ALNC	EARNINGS UPDATES: Northcoders swings to profit; AB Dynamics ups payout
25/4/2023	07:00	UKREG	Iofina PLC 2022 FULL YEAR RESULTS
12/4/2023	17:03	ALNC	IN BRIEF: Iofina continues to perform well in quarter one
12/4/2023	07:00	UKREG	Iofina PLC Production Update
20/2/2023	07:00	UKREG	Iofina PLC Director/PDMR Shareholding
06/2/2023	10:13	ALNC	IN BRIEF: Iofina shares up as eyes earnings to be ahead of market view

More Iofina News

Iofina Investors Iofina Takeover Rumours

Iofina (IOF) Discussions and Chat

Iofina Forums and Chat

Date	Time	Title	Posts
02/6/2023	15:58	Iofina - US Iodine producer	7,818
15/5/2023	16:17	Iofina	44,906
24/2/2023	11:48	Iofina recovery	7,066
04/12/2022	16:41	iofina iodine and Canabis oil	11,159
11/11/2021	08:36	IOF tipsters	2,655

Add a New Thread

Iofina (IOF) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
15:00:24	34.17	5,853	1,999.97	O
14:52:21	34.17	1,000	341.70	O
14:32:10	34.17	1,502	513.23	O
14:17:19	34.17	7,298	2,493.73	O
12:43:50	34.50	4	1.38	O

View all Iofina trades in real-time

Iofina (IOF) Top Chat Posts

Top Posts
Posted at 24/5/2023 15:29 by antoniogramschi Yes Stalin. Share prices go up when there are more buyers than sellers. Charts are a very useful tool for showing share price action and to predict movements. Read Full Thread Follow Reply
Posted at 23/5/2023 18:43 by antoniogramschi From a chart point of view, the share price hasn't peaked - we are testing higher highs and higher lows. The share price is forming the perfect chart. Coming back from today's high is healthy and the uptrend is intact. From a fundamentals point of view, io9 is upto 5 weeks away with potential for 100-150mt per year. Plus we have possibility of news of io10 and the bod's commitment to one new plant a year. It's looking great for iofina. Expect a period of consolidation in the share price though before the next leg up. Read Full Thread Follow Reply
Posted at 28/4/2023 08:43 by naphar Where’s the problem if these are really options with an exercise price of current market price? It’s incentivising management to grow the company and improve the share price. It would be nice if the strike price was above the current share price, sure, but that’s not what I have seen in my corporate career. Tom has the opportunity to gain £180k less all the taxes if he can get the share price to £1 in the next 10 years or until 90 days after he retires/leaves. Granted he is being given option every year now, it will be part of his remuneration package. They aren’t being granted RSUs, ie Tom hasn’t just been given the best part of £85k in free shares, unless I am mistaken. Read Full Thread Follow Reply
Posted at 13/4/2023 05:33 by fft The cannacord note.On page 1 they are going for $70 in H1 and $50 in H2.They also, on page 1, are going for a price of $45 in FY 24. (This does provide for a nice potential upgrade towards the end of the year). This appears to be in line with SQM forecasts from march which are mentioned. I haven't seen the latest SQM docs so can't confirm.For those who think that 45 is way too low, you should remember that in 2017 to 2021 the SQM prilled price started at 20.2 and ended at 35.7. 5 years ago investors would have loved $45 !!Page 3 provides the real meat, giving the SQM prilled iodine price and other info going back to 2017. For example, in 2021 SQM benchmark was $35.7 and IOF sold for $41.7.For FY22 SQM 59.3. IOF 70.3For FY23 (est). SQM 60. IOF 66For FY24 (est). SQM 45. IOF 69It would seem that ,on average, IOF are selling their iodine for 10% higher than the SQM benchmark price. I think that this is the blended price for crystallized iodine and for iodine derivatives. The report also includes the amount sold as crystallized iodine and the amount sold as iodine derivatives, so, taking a 15% hit from the SQM prilled price to reach the crystallized price it is possible to work out the average mark up on iodine derivatives. But, not possible to work out how profitable or margins as the cost of chemicals also includes non iodine products :-( Read Full Thread Follow Reply
Posted at 08/2/2023 22:39 by this_is_me From Master Investor hTTps://masterinvestor.co.uk/latest/smallcap-round-up-a-brace-of-bargains/?mc_cid=9c741367e0 Iofina (LON:IOF) – Robust Demand Backs Margin Improved Results For 2022 The latest Trading Update from this iodine specialist, which covers the full year to end December 2022, was very positive. Ahead of the full year’s figures being announced in May, the £53m capitalised group updated shareholders that its 2022 EBITDA figures would be materially ahead of market expectations. Global demand for iodine and iodine-based derivative products were strong throughout the whole of last year. That combined with improved production and higher pricing, resulted in better sales margins. Furthermore, iodine prices have remained steady into Q1 2023 and the group continues to see robust demand for its iodine and iodine derivatives. CEO Dr Tom Becker stated that: “2022 was a year of significant progress for Iofina. Solid iodine production performance, higher prices and strong demand for iodine, and the beginning of construction of our newest plant IO#9 are all examples of the positive momentum that the Company is carrying forward into 2023. The Board now expects 2022 EBITDA to exceed market estimates and we look forward to releasing the Company’s fully audited 2022 results in May. We are excited for the commencement of production at our IO#9 plant later in Q2 2023 which is anticipated to produce 100-150MT of crystalline iodine per annum.“ Analyst Alex Brooks at Canaccord Genuity Capital Markets rates the group’s shares as a Buy, having increased his price objective by 2.5p to 37.5p on the news. He estimates $42.5m ($39.0m) sales for the last year, with EBITDA rising to $11.0m ($6.9m), taking earnings up to 3.4c (2.5c) per share. For the year now underway he looks for $45.3m revenues, $11.7m EBITDA and earnings of 3.7c per share. Former fund manager Richard Sneller was certainly shrewd as he picked up more stock in the group in late December last year. Now with the biggest holding, almost 35m shares representing 18.2% of the Iofina equity, he will benefit from the group’s shares rising to Canaccord’s price objective. Hold very tight, they are heading higher still – they closed last night at 28.05p. (Profile 29.07.20 @ 13.5p set a Target Price of 18p) (Asterisks denote that Target Prices have been achieved Profile publication Read Full Thread Follow Reply
Posted at 08/2/2023 22:35 by this_is_me htTps://masterinvestor.co.uk/latest/smallcap-round-up-a-brace-of-bargains/?mc_cid=9c741367e0 Iofina (LON:IOF) – Robust Demand Backs Margin Improved Results For 2022 The latest Trading Update from this iodine specialist, which covers the full year to end December 2022, was very positive. Ahead of the full year’s figures being announced in May, the £53m capitalised group updated shareholders that its 2022 EBITDA figures would be materially ahead of market expectations. Global demand for iodine and iodine-based derivative products were strong throughout the whole of last year. That combined with improved production and higher pricing, resulted in better sales margins. Furthermore, iodine prices have remained steady into Q1 2023 and the group continues to see robust demand for its iodine and iodine derivatives. CEO Dr Tom Becker stated that: “2022 was a year of significant progress for Iofina. Solid iodine production performance, higher prices and strong demand for iodine, and the beginning of construction of our newest plant IO#9 are all examples of the positive momentum that the Company is carrying forward into 2023. The Board now expects 2022 EBITDA to exceed market estimates and we look forward to releasing the Company’s fully audited 2022 results in May. We are excited for the commencement of production at our IO#9 plant later in Q2 2023 which is anticipated to produce 100-150MT of crystalline iodine per annum.“ Analyst Alex Brooks at Canaccord Genuity Capital Markets rates the group’s shares as a Buy, having increased his price objective by 2.5p to 37.5p on the news. He estimates $42.5m ($39.0m) sales for the last year, with EBITDA rising to $11.0m ($6.9m), taking earnings up to 3.4c (2.5c) per share. For the year now underway he looks for $45.3m revenues, $11.7m EBITDA and earnings of 3.7c per share. Former fund manager Richard Sneller was certainly shrewd as he picked up more stock in the group in late December last year. Now with the biggest holding, almost 35m shares representing 18.2% of the Iofina equity, he will benefit from the group’s shares rising to Canaccord’s price objective. Hold very tight, they are heading higher still – they closed last night at 28.05p. (Profile 29.07.20 @ 13.5p set a Target Price of 18p) (Asterisks denote that Target Prices have been achieved Profile publication) Read Full Thread Follow Reply
Posted at 06/2/2023 15:53 by zendo102 beercapfn, If you are a trader, you don't buy into today's share price strength, you sell. Then, you wait patiently until the froth has blown away and the share price inevitably drifts down over the next few weeks. Only when it reaches your target price do you buy. This would have been the best strategy over the last few years by far. Traders would say that buying into today's price rises is for mug punters only. (And if the share price doesn't go down? Well, there's always another share somewhere.) Read Full Thread Follow Reply
Posted at 16/1/2023 14:34 by joestalin For a "blue Monday", the IOF share price seems to be bucking the trend. I wonder if there is any substance to it. Read Full Thread Follow Reply
Posted at 12/1/2023 23:13 by dk37 A good review with some further comment on the Cannacord report Iofina [LON:IOF], the Colorado-headquartered AIM-listed chemical company, with most of its operations in Oklahoma published an update that outlines its production estimates and timeline on the construction of its new production facilities. As previously reported, Iofina currently operates five iodide extraction plants in the oilfields of Oklahoma and announced in 4Q22 the construction of a sixth plant in Western Oklahoma, IO#9. The company said that it has assembled the necessary materials and staff and started construction on IO#9, which it hopes to complete in 2Q23. Speedy payback As reported, Iofina secured debt financing in July 2022 to support the construction of the new extraction plant and the plant will come into immediate operation, contributing to revenues from the point of commissioning and would be in a position of full payback within two years. The company was targeting between 100 tonnes (T) and 150T of crystalline iodide production from the new site a year. Frontier Developments shares tumble as results disappoint This online gaming stock looks like a long term buy Premier African Minerals confident of lithium production this quarter Tom Becker, Iofina’s chief executive had previously told The Armchair Trader: “We could develop three or four more plants on this site in the next three-to-five years,” he said. New supply lines Becker said in a statement to the market that the company was sourcing additional brine supplies from oil and gas operators in the region with a view to building another extraction plant, IO#10 later this year. Becker said: “Negotiations continue to progress positively in line with Iofina’s commitment to achieve further expansion of iodine production capacity in the short term.” As previously reported, Iofina was targeting 255T to 275T production for 2H22. The company exceeded this target by producing 282T of crystalline iodide in the period, with total production for 2022 being 516T. Iofina has also been helped by an uptick in the global iodine prices increasing from USD50/Kg at the start of 2022 to USD70/Kg where it stabilised for most of the rest of the year. The company said that it expects prices to stay around the USD70/kg level for at least the first part of2023 as a result of tight global supply. Becker said that the company is aiming to produce between 235T and 250T of iodide in the first half of 2023, but noted that historically 1H production has always been lower than 2H production due to low temperatures in the winter months. Iofina opened trading today at 22.75p and has offered a year-to-date return of 12.2%, a one-year return of 15% with the company’s shares ranging between 13.53p and 28.5p over a 52-week period. The company has a market capitalization of GBP39.8m LSE:IOF quotes by TradingView Trade IOF on Hargreaves Lansdown or IG Iofina is the second-largest iodine producer in the US. A large amount of the world’s iodine comes from Chile, where bedrock in the Atacama Desert is blasted, crushed and leached in evaporation ponds, which is quite an intrusive, destructive and polluting process. Iofina, on the other hand chemically-extracts iodide from the brines rejected by the O&G producers, and then reinjects the wastewater back into the earth into empty oil wells. Increased global demand The largest current single use for iodine currently is in X-rays and medical imaging, where iodine targets soft tissue areas in the body, allowing medics to analyse damage or injury in these areas through biomedical imaging. This is leading to an increased global demand, especially as Asia upgrades its healthcare infrastructure. It is also used as a disinfectant and as a health supplement. Becker said the tech industry is experimenting with iodine in the manufacture of batteries for renewable energy projects and electric vehicles. Iodine is found in seawater and was traditionally extracted from seaweed, but it is also found in the remnants of prehistoric seas, as briny deposits sitting above layers of hydrocarbon-rich deposits, and in bedrock. Currently global production of iodine is 36,000T to 37,000T. Broker Canaccord Genuity recently published a research note on Iofina. Canaccord said: “Demand for the group’s products remain strong and the benchmark iodine price closed the year still at USD70/kg […] we have made minor changes to our 2022E numbers reflecting the higher production levels and we continue to see our forecasts as conservative. In particular, we are assuming an average iodine price for 2022E of USD55/kg (against a spot of USD70/kg) and production volume up just 7%.” The broker continued: “[This] could be entirely delivered just by the additional contribution on IO#9. […] we believe the group’s successful transition to not only being free cash flow positive, but with an exceptionally robust balance sheet has been underrated by the market.” Canaccord rate Iofina as a ‘Buy’ with a target price of 35p trading at a multiple of 13x to 15x and “increasing confidence for the outlook for the current year.” Deshe rate Iofina as a ‘Buy’ stating: “Iofina plc released impressive 2Q22 results on 26th September 2022. Specifically, their growth, value, and income factors indicate a well-planned and balanced effort, which is generating exciting growth. These results lead us to believe that there should be significant upside potential for the stock. Therefore, they earned a total score of 85 out of 100 and a ‘Buy’ recommendation.̶1;4 Read Full Thread Follow Reply
Posted at 11/1/2023 21:27 by this_is_me htTps://masterinvestor.co.uk/equities/small-cap-catch-up-iodine-and-global-specialist-vacancies/?mc_cid=1c65306e7a Iofina (LON:IOF) – Strong Demand Throughout Last Year As I suggested last week, the snapping-up of a few more shares in this specialty chemicals business by its currently largest shareholder was a sensible move. Former fund manager Richard Sneller now has nearly 35m shares in the group, representing 18.2% of its equity. The vertically integrated group specialises in the production of iodine and the manufacturing of specialty chemical products. It is the second largest producer of iodine in North America, with operations in Kentucky and Oklahoma. Iodine is in demand for uses in X-Ray contrast media, polarising film, catalysis and as an antiseptic and biocidal agent. In a Q4 Corporate Update issued on Monday, the company stated that demand for its products had remained strong, helped by a rising iodine spot price which had moved up from $50/kg at the beginning of last year, to a closing level at around $70/kg at the year end. What is more, prices are expected to stay high with global supply being restricted. Boss Dr Tom Becker stated that: “Iofina had a strong end to 2022, with H2 iodine production surpassing our initial target and product sales remaining robust. As such, the Company is pleased with the expected outturn of its business in 2022. Looking ahead, with brine water supplies to our plants consistent and IO#9 on track for completion and start-up in Q2 2023, Iofina Resources will have the capacity to deliver a significant increase in crystalline iodine production going forward. Market dynamics for raw Iodine remain very favourable and coupled with the demand for our specialty products, the Board of Iofina is confident in the current outlook for the new year.” After Monday’s Update analyst Alex Brooks at Canaccord Genuity maintained his Buy rating for the group’s shares, with a price objective of 35p, against last night’s closing price of 22.5p. His estimates for the 2022 December year end are for sales of $42.1m ($39.0m), with adjusted pre-tax profits having risen from $4.9m to $6,6m, worth 2.5c (2.5c) in earnings per share. For the current year Brooks goes for $44.5m sales, $8.4m profits and 3.2c per share in earnings. On Monday morning the group’s shares hit 24.45p in reaction to the strong demand news, before easing back on gentle profit-taking. Reflecting the current year prospects, could the shares rise back to hit the 28p level hit last June. Hold very tight. Read Full Thread Follow Reply

Iofina share price data is direct from the London Stock Exchange

Your Recent History

LSE

IOF

Iofina

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230602 15:18:04